Multi-Center Studies. CRO, upon Pfizer’s prior instructions, may end Study Subject enrollment early if the total enrollment needed for a multi-center study has been achieved before the end of the enrollment period for this Study. 4.1
Multi-Center Studies. Sponsor may discontinue patient enrollment if the total enrollment needed for a multi-center Trial has been achieved.
Multi-Center Studies. If Study is part of a multi-center trial, Principal Investigator and Institution agree that the first Publication is to be a joint Publication covering all Study sites, and that any subsequent Publications by Principal Investigator will reference that primary Publication. However, if a joint manuscript has not been submitted for publication within 12 months of completion or termination of Study at all participating sites, Principal Investigator is free to publish separately, subject to the other requirements of this Section 15.
Multi-Center Studies. The Sponsor may end Study Subject enrollment early if the total enrollment needed for a multi-center study has been achieved before the end of the enrollment period for the Study. [Use the alternative text above if the study team has not set an enrollment minimum or maximum.]
Multi-Center Studies. The Trial is multi- center and Sponsor may discontinue patient enrollment if the total enrollment needed for a Trial has been achieved. 7.1 Multicentrické studie Klinické hodnocení je multicentrické a zadavatel může zastavit zařazování pacientů, bylo-li dosaženo celkového potřebného počtu subjektů klinického hodnocení.
Multi-Center Studies. If Study is part of a multi-center trial, Principal Investigator and Institution agree that the first Publication is to be a joint Publication covering all Study sites, and that any subsequent Publications by Principal Investigator will reference that primary Publication. However, if a joint manuscript has not been submitted for publication within 12 months of completion or termination of Study at all participating sites, Principal Investigator is free to publish separately, subject to the other requirements of this Section 15. 15.2 Multicentrické studie. Jestliže je Studie součástí multicentrického hodnocení, Hlavní zkoušející souhlasí, že první Publikací bude společná Publikace zahrnující všechna pracoviště Studie a že následné Publikace Hlavního zkoušejícího budou odkazovat na tuto primární Publikaci. Nicméně pokud nebyl společný rukopis předložen k publikaci během 12 měsíců od dokončení nebo ukončení Studie všemi zúčastněnými pracovišti, může Hlavní zkoušející publikovat samostatně pod podmínkou splnění ostatních požadavků tohoto článku 15.
Multi-Center Studies. Sponsor may discontinue patient enrollment if the total enrollment needed for a multi-center Trial has been achieved. 7.1 Štúdie vo viacerých centrách. Sponzor má právo prestať zapisovať pacientov v prípade, že v Skúšaní vo viacerých centrách už bol dosiahnutý celkový počet potrebných zápisov.
Multi-Center Studies. The Trial is multi-center and Sponsor may discontinue patient enrollment if the total enrollment needed for a Trial has been achieved. 8. Informed Consent. Provider and Principal Investigator will obtain a written Informed Consent Form (“ICF”) for each Trial Subject explaining the Trial Subject’s rights in connection with its relationship with the Provider and Principal Investigator. Provider and Principal Investigator will maintain a signed original of that ICF in the Trial Subject’s record. Provider and Principal Investigator will provide Sponsor an opportunity to review and approve the content of the ICF, including any revisions made during the course of the Trial, before it is used. Provider and Principal Investigator will allow Sponsor or its designee to inspect signed ICFs or photocopies thereof during monitoring visits or audits. Provider and Principal Investigator will submit any modifications it may propose to the ICF to Sponsor for review and written approval by Sponsor before submitting the ICF for IEC approval. The Principal Investigator will ensure that every Trial Subject signs an ICF approved by Sponsor and the Provider's IEC before the Trial Subject begins participating in the Trial. When required, the approved ICF will be modified to reflect amendments to the Protocol. 9.
Multi-Center Studies. Institution and Investigator have been made aware of that this is a multi-center Study and therefore a competitive recruitment situation shall apply. Sponsor may end Study Subject enrollment early if the total enrollment needed for a multi-center study has been achieved before the end of the enrollment period for this Study.
Multi-Center Studies. Sponsor may discontinue patient enrollment if the total enrollment needed for a multi- center trial has been achieved or there is a risk of an uneven stratification across regions. 7. Zaradenie subjektov do hodnotenia. Inštitúcia súhlasí, že zaradí do Hodnotenia Subjekty hodnotenia v súlade s Protokolom. 7.1
